Additional information required before initiation of Tripeps' ChronSeal phase II study

Additional information required before initiation of Tripeps' ChronSeal phase II
study

Prior to initiating Tripeps' ChronSeal phase II study, the Medical Products
Agency (MPA) demands additional information regarding the Japanese production
facility and a revision of the study protocol. These measures are expected to be
concluded during the first half of April. Under condition that these measures
are deemed for an approval, a new application is expected to be filed during
April. If further study documentation is required, a new application is expected
to be filed during 2008. 

“Previously, two clinical pilot studies have been concluded where patients who
received active treatment had a 60 percent healing after one week treatment.
Earlier this year we also successfully concluded a safety study on animals of
the antibiotic free-formulation of ChronSeal. This - in combination with our
assessment that we in short time will be able to comply with the MPA demands -
makes us keep high expectations on the product and, as previously stated, that
we should be able to initiate the study under 2008”, says Jan Nilsson, CEO
Tripep AB.


For more information, please contact:
Jan Nilsson, CEO, Tripep AB
Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63
E-mail: jan.nilsson@tripep.se

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se

TO THE EDITORS
About Tripep
Tripep develops drugs against chronic disease based on proprietary and other
parties' patented and patent pending technologies. Tripep is focusing on the
following research projects; wound healing therapy ChronSeal and a therapeutic
vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology
platform. The Tripep share is admitted to trade on First North. Remium AB is
Certified Adviser for Tripep AB.  For more information, please refer to the
company's website: www.tripep.se.
About ChronSeal 
ChronSeal is a HGF-based (Hepatocyte Growth Factor) treatment for chronic leg
wounds, a rapidly increasing problem among the elderly population of the Western
World. In cooperation with Tripep's partners Kringle Pharma and Zelmic AB, a new
formulation has been developed that enables the use of ChronSeal without it
being combined with antibiotics. The new formulation allows for controllable
release of HGF, while avoiding antibiotic resistance, another rapidly growing
problem. An application for a patent pertaining to an antibiotic-free
formulation of ChronSeal was filed in the US in January 2008.

More than four million people in the US and Europe are currently suffering from
chronic leg wounds. This corresponds to a market value of approximately SEK12
billion. Accordingly, the medical need is considerable and the growth rate is
high, factors that are expected to provide ChronSeal with substantial commercial
potential.